Showing results (101-110 of 236) with videos related to
Sort By:
Pageof 24
Cancer Research|July 15, 1988
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cellsC L Arteaga, A K Tandon, D D Von Hoff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifenG Arpino, H L Weiss, G M Clark, et al.Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|December 1, 1994
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expressionK B Reddy, D Yee, S G Hilsenbeck, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 12, 2005
Optimizing hospital use of intravenous insulin therapy: improved management of hyperglycemia and error reduction with a new nomogramLillian F Lien, Susan E Spratt, Zinta Woods, et al.European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trialsL Mauriac, J E Pippen, J Quaresma Albano, et al.Breast Cancer Research and Treatment|January 1, 1992
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot studyK S Albain, S Green, M LeBlanc, et al.Breast Cancer Research and Treatment|June 27, 2003
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapyI Vergote, J F R Robertson, U Kleeberg, et al.Breast Cancer Research and Treatment|July 1, 1988
Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse modelC K Osborne, C R Ross, E B Coronado, et al.Breast Cancer Research and Treatment|January 1, 1994
Prognostic factors: rationale and methods of analysis and integrationG M Clark, S G Hilsenbeck, P M Ravdin, et al.Cancer|August 1, 1976
Extranodal presentation of non-Hodgkin's lymphomas in the testisP V Woolley, C K Osborne, J A Levi, et al.Pageof 24